Elekta Stock - New mid-term targets and strategy at Capital Markets Day
17.06.2026 - 17:53:47 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 17:50 CET. Details in the imprint.
Elekta (SE0000163628) outlines new mid-term financial targets and a detailed fiscal 2026/27 outlook around its Capital Markets Day in Stockholm. According to an IR-based update and financial press reports, the Swedish medtech group now ties its strategy more tightly to concrete growth and margin goals.
All news and data on Elekta stock
Key figures, news and background on Elekta’s radiation-therapy business and stock performance at a glance.
What Elekta announced today
According to an Elekta communication summarized via Modular Finance, the company today presented new mid-term financial targets alongside a more detailed outlook for fiscal year 2026/27 ahead of its Capital Markets Day in Stockholm. The TradingView-sourced IR summary cites expected constant-currency sales growth of 2-4% in FY 2026/27 and an adjusted EBIT margin of 12.5-13.5%.
The updated 2026/27 outlook is described as consistent with figures signaled at Elekta’s Q4 2025/26 results, but now framed more precisely for revenue growth and profitability bands. Investing.com reports that the company also discussed mid-term ambitions for sales expansion and margin improvement beyond that fiscal year.
How the market reacts to CMD targets
Financial press coverage highlights that Elekta’s new targets arrived in a market with relatively high expectations for its Capital Markets Day, which sharpened investor focus on the ambition level of management’s plan. One Investing.com article notes that Elekta B shares were recently down around 3-4% intraday, trading close to SEK 49.5.
Commentary there points to a combination of cautious analyst sentiment, elevated short interest and a broadly risk-off backdrop as factors that may have amplified the share reaction to what some investors viewed as only moderately ambitious mid-term financial goals.
Operational strategy and Wednesday focus
Strategically, management aims to balance incremental sales growth with disciplined margin expansion, using its installed base, software and service contracts as key drivers, according to the Capital Markets Day framing. MarketScreener’s synopsis also cites Elekta’s forecast of 2-4% constant-currency sales growth for 2025/26, underscoring continuity across the planning horizon.
The Wednesday focus for investors is on whether Elekta can execute on its operational agenda: expanding access in emerging markets, defending share against large US and European rivals, and steadily improving profitability from a base that some analysts still view as relatively soft.
The product behind the stock
Elekta generates most of its revenue from advanced radiation-therapy systems such as the Elekta Unity MR-Linac and Versa HD linear accelerators, complemented by oncology software platforms that help hospitals plan, deliver and manage cancer treatments efficiently across their workflows.
Where the stock trades today
The shares of Elekta (SE0000163628) trade on Nasdaq Stockholm at SEK 49.60 as of 06/17/2026, 17:30 CET.
Key facts on Elekta stock
- Company: Elekta AB (publ)
- ISIN: SE0000163628
- WKN: 893114
- Ticker: EKTA B
- Venue: Nasdaq Stockholm
- Price (as of 06/17/2026, 17:30 CET): 49.60 SEK
- Market cap: 19,000,000,000 SEK (as of 06/17/2026)
- Sector / Industry: Health Care / Medical Equipment
- Index membership: OMX Stockholm Benchmark
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
